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Introduction
Depression is characterized by a wide range of diverse symptoms, the severity of which 
can be quantified by various depression rating scales, such as the Montgomery Asberg 
Depression Rating Scale. Analyses of the individual items of this scale in patients 
treated with the selective serotonin reuptake inhibitors (SSRIs) have shown that not 
all items respond equally or with the same time of onset of improvement (Table 1).1,2 
The items which respond less well or more slowly with SSRIs include lassitude, loss 
of energy, retardation of thoughts or actions, as well as concentration difficulties and 
loss of alertness. The loss of interest or pleasure that depressed patients experience 
(anhedonia) also responds poorly to SSRIs, and patients often complain of emotional 
indifference or blunting. Certain sleep difficulties are sometimes worsened by SSRIs. 
Appetite loss can be aggravated by certain SSRIs, an effect which can be made worse 
by nausea at the beginning of treatment.
Similarly, a cluster of common depressive symptoms of “decreased positive 
affect”, including loss of interest or pleasure, fatigue, loss of energy, and decreased 
motivation, which do not respond adequately to serotonergic antidepressants, have 
been identified. Antidepressants that enhance noradrenergic (and dopaminergic) activ-
ity appear to offer a therapeutic advantage over serotonergic antidepressants in the 
treatment of these symptoms.3
Based mainly on theoretical considerations, the symptoms of depression have been 
associated with deficiencies of one or more of the monoamine neurotransmitters.4 In 
this scheme, decreased concentration, retardation, loss of energy, lassitude, tiredness, 
and reduced self-care are associated with decreased noradrenergic activity (Table 1). 
Thus, clinical and theoretical considerations combine to define the noradrenergic 
symptom cluster, ie, decreased concentration, retardation, loss of energy, lassitude, 
tiredness, and reduced self-care.
This supplement, which is based on a symposium held at the International Forum on 
Mood and Anxiety at Vienna in November 2010, discusses the noradrenergic symptom 
cluster, the importance of these symptoms in the burden of depression, their clinical 
and neuropharmacological nature, and how these symptoms can be improved by the 
serotonin and noradrenaline reuptake inhibitor (SNRI) antidepressant, milnacipran.
In the first paper, Lépine presents recent epidemiological data on the prevalence 
of depression and the associated risk of mortality by suicide, as well as cardiovascular 
and other deaths. Studies of the familial and financial burden of depression show an Neuropsychiatric Disease and Treatment
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increased risk of loss of productivity and absenteeism in 
depression, which frequently result in decreased income or 
unemployment. The importance of the burden of depression 
is underlined by the estimation of the World Health Organiza-
tion that, by 2030, unipolar major depression will become the 
leading worldwide cause of disease burden.
The second paper by Moret examines the importance of 
norepinephrine in the etiology of depression. Evidence for 
the involvement of norepinephrine including recent studies 
on neuronal pathways and symptoms, highlights the deter-
minant role of norepinephrine in key symptoms, including 
executive functioning, which regulates cognition, motivation, 
and intellect, which are of fundamental importance in social 
relationships, that are impoverished in depression.
In the third paper, Blier explains the reciprocal interactions 
between the serotonin system and norepinephrine and dopamine 
neurotransmission. Enhanced serotonin transmission, as during 
SSRI treatment, attenuates noradrenergic and dopaminergic 
activity. This can contribute to the residual symptoms of 
fatigue and lack of energy that are often reported by patients 
responding to SSRI. Milnacipran, by increasing norepinephrine 
(and dopamine), as well as serotonin neurotransmission is 
less likely to induce or aggravate such residual symptoms. 
Milnacipran’s potentiation of norepinephrine and serotonin 
(and indirectly dopamine) neurotransmission contributes 
to its antidepressant action, while its attenuation of phasic 
noradrenergic reactivity reduces the risk of anxiety.
In the fourth and final paper, Kasper discusses the impor-
tance of social dysfunction in depressed patients which can 
lead to family disruption, social isolation, absenteeism, and 
potential unemployment. The symptoms of the noradrenergic 
symptom cluster are important factors in social dysfunction, 
and antidepressants with a strong noradrenergic component 
improve social functioning. Preliminary data suggest that 
milnacipran improves social functioning to a greater extent 
than SSRIs.
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Table  1  Comparison  of  core  symptoms  of  depression  which 
respond less well or more slowly to SSrIs and depressive symp  toms 
specifically related to a deficiency of noradrenergic neurotrans­
mission
A.   Core symptoms of depression which respond less well or more 
slowly to SSrIs
• Lassitude
• Loss of energy
• retardation of thoughts and actions
• Concentration difficulties, loss of alertness
• Loss of interest, anhedonia, emotional indifference or blunting
• Sleep difficulties, sometimes worsened by SSRIs
• Appetite loss, sometimes worsened by nausea caused by SSrIs
B.   Depressive symptoms specifically related to a deficiency of noradrenergic 
neurotransmission
• Lassitude
• Loss of energy
• retardation of thoughts and actions
• Concentration difficulties, loss of alertness
• Tiredness
Abbreviation: SSrIs, selective serotonin reuptake inhibitors.